11. Assay Procedure Continued...

9. Add 100μl of Stop Solution (Reagent 5) to each well. To allow equal reaction times, the Stop Solution should be added to the wells in the same order as the TMB Substrate.

10. Read the optical density (OD) of each well at 450nm in a microplate reader within 10 minutes. A 620nm filter may be used as a reference wavelength.

12. Quality Control

Quality control data is supplied on the lot-specific QC certificate included in the kit.

The positive control is intended to monitor for substantial reagent failure.

Any well positive by spectrophotometer but without visible colour should be cleaned on the underside and re-read. If OD values below zero are observed, the wavelengths used should be verified, the reader re-blanked to air and the measurements repeated.

13. Interpretation of Results

Quantitative Results
Plot the OD of each standard against its concentration and draw the best-fit curve through the points. Read the unknowns off this curve.

Quantitative Results
Plot the OD of each standard against its concentration and draw the best-fit curve through the points. Read the unknowns off this curve. Through the points. Read the unknowns off this curve.

Values greater than 2 U/ml are considered positive. Values between 11 – 13 U/ml are considered indeterminate. Values greater than 13 U/ml are considered positive. Samples producing values greater than 200 U/ml should be repeated at a higher dilution e.g. 1:200.

Qualitative Results
Samples with ODs greater than that of the 11 U/ml standard are positive.

14. Limitations of the Procedure

1. When negative anti-cardiolipin antibodies are found in the presence of clinical indications, a lupus anticoagulant or other additional testing is indicated.

2. Diagnosis cannot be made on the basis of anti-cardiolipin antibodies alone. These results must be interpreted in conjunction with clinical indications.

15. Performance Characteristics

Assay Sensitivity
1.9 U/ml

16. Reproducibility

Within Assay Precision
CV%: 5%

Between Assay Precision
CV%: 9%

17. Method Summary

- Dilute sera 1:100 with Sample Diluent (Reagent 1)
- Dispense Standards, the Positive Control and the diluted sample into the microplate wells
- Incubate for 30 minutes at room temperature.
- Wash the wells three times
- Dispense 100μl of Conjugate (Reagent 3) into each well
- Incubate at room temperature for 30 minutes
- Wash the wells four times
- Add 100μl of TMB Substrate (Reagent 4) to each well
- Incubate at room temperature for 10 minutes
- Add 100μl Stop Solution (Reagent 5) to each well
- Read the optical density at 450nm (single wavelength) or 450/620nm (dual wavelength).

18. Further Reading

Clinical and Experimental Immunology, 1987, 68: 222.
American Journal of Medicine, 1995, 98: 559-565.
Lancet, 1983: 1214-1214

Eden Research Park, Henry Crabb Road, Littleport, Cambridgeshire, CB6 1SE, UK Tel: 44(0)1353 862220 Fax: 44(0)1353 863310
Email: support@elisa.co.uk Web: www.omega.diagnostics.com

Genesis Diagnostics Ltd is a subsidiary of Omega Diagnostics Group PLC

4Units are arbitrary

Total Anti-Cardiolipin Screen ELISA Kit
Quantitative/qualitative assay for total cardiolipin antibodies

Product Code: GD028
For in vitro Diagnostic Use
2. Other Equipment Required

Test tubes for dilution ● graduated cylinder for preparing wash buffer ● precision pipettes and disposable tips to deliver 10µl, 100µl, 1ml ● ELISA microplate washer or multi-channel pipette or wash bottle ● distilled or de-ionised water ● absorbent paper ● ELISA microplate reader with 450nm and optional 620nm reference filter. Alternatively, a suitable, self-validated automated system may be used.

Instrumentation, whether manual or automated, should meet the following criteria: pipettes with better than 3% imprecision with no carry over between pipetting steps; microplate washers should remove 99% of fluid; automated machines should minimise time between washing and adding the next reagent.

3. Intended Use

The Total Anti-Cardiolipin kit is a rapid ELISA method for the detection of autoimmune anti-cardiolipin antibodies. It is intended as an aid to the diagnosis and monitoring of thrombotic diseases associated with primary antiphospholipid syndrome (APS), and to the diagnosis of APS associated with systemic lupus erythematosus (SLE) and lupus-like disorders.

4. Explanation of the Test

APS is the most frequent cause of acquired thrombophilia. Patients with this disorder frequently have anti-cardiolipin antibodies (aCL) in their blood and are predisposed to venous and arterial thrombosis, thrombocytopenia and, in women, recurrent foetal loss. Although first described in patients with SLE, aCL disorder frequently have anti-cardiolipin antibodies in their blood and are predisposed to venous and arterial thrombosis, thrombocytopenia and, in women, recurrent foetal loss. Although first described in patients with SLE, aCL has not been exclusively associated with lupus patients but also occur frequently in non-lupus patients with primary APS.

Compared with infection-associated aCL, autoimmune aCL require the presence of the co-factor (J2-glycoprotein 1 (J2-GP1) for optimal binding. Therefore, the antigen preparation used in the Genesis aCL ELISA assays consists of purified cardiolipin in configuration with J2-GP1. Assays that omit the co-factor are thought to detect aCL associated with non-autoimmune disorders e.g. syphilis, leprosy and infectious mononucleosis.

5. Principle of the Test

Diluted serum samples are incubated with cardiolipin/J2-GP1 immobilised on microtitre wells. After washing away unbound serum components, goat anti-human IgAGM conjugated to horseradish peroxidase is added to the wells, and this binds to surface-bound antibodies in the second incubation. Unbound conjugate is removed by washing, and a solution containing 3,3’,5,5’-tetramethylbenzidine (TMB) and enzyme substrate is added to trace specific antibody binding. Addition of Stop Solution terminates the reaction and provides the appropriate pH for colour development. The optical densities of the standards, positive control and samples are measured using a microplate reader at 450nm.

6. Safety Precautions

1. All reagents in this kit are for in vitro diagnostic use only.
2. Only experienced laboratory personnel should use this test. The test protocol must be followed strictly.
3. CAUTION: the device contains material of human and animal origin and should be handled as a potential transmitter of diseases. All human source material used in the preparation of standards and control for this product have been tested and found negative by ELISA for antibodies to HIV, HbsAg and HCV. No test method, however, can offer complete assurance that infectious agents are absent. Therefore, all reagents containing human material should be handled as if potentially infectious. Operators should wear gloves and protective clothing when handling any patient sera or serum based products.
4. Reagents of this kit contain anticoagulant and the Substrate solution contains 3,3’,5,5’-tetramethylbenzidine. Avoid contact with the skin and eyes. Rinse immediately with plenty of water if any contact occurs.
5. The Stop Solution contains 0.25M sulphuric acid. Avoid contact with skin and eyes. Rinse immediately with plenty of water if contact occurs.
6. Any liquid that has been brought into contact with potentially infectious material to be discarded in a container with a disinfectant. Dispose of plates and specimens as clinical waste. Any unused reagents should be flushed away with copious amounts of water. Disposal must be performed in accordance with local legislation.

7. Technical Precautions

1. Strips and solutions should not be used if the foil bag is damaged or liquids have leaked.
2. Allow all reagents and the microplate to reach room temperature before use. Ensure that the microplate foil bag containing any unused strips is well sealed and contains the desiccant to avoid moisture. Store at 2 – 8°C after use.
3. When setting up the instrument and dead volume of robot pipette
4. Include the Positive and Negative Control in every test run to monitor for reagent stability and correct assay performance.
5. Strictly observe the indicated incubation times and temperature.
6. Ensure that no cross-contamination occurs between wells. Keep all pipettes and other equipment used for Conjugate completely separate from the TMB Substrate reagent.
7. When pipetting Conjugate or TMB Substrate, aliquots for the required numbers of wells should be taken to avoid multiple entry of pipette tips into the reagent bottles. Never pour unused reagents back into the original bottles.
8. Do not allow microwells to dry between incubation steps.
9. Strictly follow the described wash procedure. Insufficient washing may cause high background signal.
10. Avoid direct sunlight and exposure to heat sources during all incubation steps.
11. Replace colour-coded caps on their correct vials to avoid cross-contamination
12. It is important to dispense all samples and controls into the wells without delay. Therefore ensure that all samples are ready to dispense.

8. Shelf Life and Storage Conditions

On arrival, store the kit at 2 - 8°C. Once opened the kit is stable for 3 months (or until its expiry date if less than 3 months). Do not use kits beyond their expiry date. Do not freeze any kit component. The diluted Wash Buffer has a shelf life of 3 months if stored in a closed bottle at 2 - 8°C.

9. Specimen Collection and Storage

Serum and plasma samples may be used and should be stored at -20°C for long-term storage. Frozen samples must be mixed well after thawing and prior to testing. Repeated freezing and thawing can affect results. Addition of preservatives to the serum sample may adversely affect the results. Microbiologically contaminated, heat-treated or specimens containing particulate matter should not be used. Grossly haemolysed, icteric or lipaemic specimens should be avoided.

10. Preparation of Reagents

Dilute the Wash Buffer (Reagent 2) 1:9 in distilled water to make sufficient buffer for the assay run e.g. add 50ml wash buffer concentrate to 450ml water.

11. Assay Procedure

1. Dilute patient samples 1:100 in Sample Diluent (e.g. 10µl serum plus 1ml diluent).
2. Assemble the number of strips required for the assay.
3. For quantitative assays, dispense 100 µl of each Standard, the Positive Control and the diluted patient samples into appropriate wells.
4. Incubate for 30 minutes at room temperature.
5. After 30 minutes, decant or aspirate the well contents and wash the wells 3 times using automated washing or the manual wash procedure (see below). Careful washing is the key to good results. Do not allow the wells to dry out.

Manual Wash Procedure

Empty the wells by inversion. Using a multi-channel pipette or wash bottle, fill the wells with wash buffer. Empty by inversion and blot the wells on absorbent paper. Repeat this wash process 2 more times.

6. Dispense 100µl of Conjugate (Reagent 3) into each well. Incubate the wells for 30 minutes at room temperature.
7. After 30 minutes, discard the well contents and carefully wash the wells 4 times with Wash Buffer. Ensure that the wells are empty but do not allow to dry out.
8. Using a repeating dispenser, rapidly dispense 100µl of TMB Substrate (Reagent 4) into each well. Incubate the plate for 10 minutes.